GIS:FRA
Gilead Sciences, Inc
153,40 EUR
arrow_upward
+0,35%(+0,54) 1 zi
12 nov., 16:19:22 GMT+1 · EUR
search
Toate simbolurile
| Simbol | Preț | Modificare | Modificare % |
|---|
insights_autoSe generează principalele statistici pentru GIS...
Deschide
153,56 EUR
Mare
153,58 EUR
Mic
153,40 EUR
Capitalizarea bursieră
210,55 mld.
Volum mediu
198,00
Volum
95,00
Prețul ridicat pe 52 de săptămâni
157,14 EUR
Prețul redus pe 52 de săptămâni
100,42 EUR
Nr. de angajați
17 K
Deschide
153,56 EUR
Mare
153,58 EUR
Mic
153,40 EUR
Capitalizarea bursieră
210,55 mld.
Volum mediu
198,00
Volum
95,00
Prețul ridicat pe 52 de săptămâni
157,14 EUR
Prețul redus pe 52 de săptămâni
100,42 EUR
Nr. de angajați
17 K
Subiecte de știri
Din surse web și de la parteneri de știri
The Globe and Mail
·
acum 32 de minute
Can Gilead Sciences' HIV Business Fuel Sustainable Long-Term Growth?
Investing.com
·
acum 5 ore
Argus raises Gilead Sciences stock price target on pipeline strength
Yahoo Finance
·
acum 5 ore
Gilead Brings HIV Prevention to the 27th Annual Latin GRAMMY Awards®
Yahoo Finance
·
acum 5 ore
Gilead Sciences, Inc. (GILD) Stock Forecasts
Profil
Gilead Sciences, Inc. is an American biopharmaceutical company headquartered in Foster City, California, that focuses on researching and developing antiviral drugs used in the treatment of HIV/AIDS, hepatitis B, hepatitis C, influenza, and COVID-19. It also develops medicines in therapeutic areas such as oncology and inflammation and cell therapy.
In 1987, Michael L. Riordan founded the company under the name Oligogen. The original name was a reference to oligonucleotides, small strands of DNA used to target genetic sequences. Gilead held its initial public offering in 1992, and successfully developed drugs including Tamiflu and Vistide that decade.
In the 2000s, Gilead began evolving from a biotechnology company into a large pharmaceutical company, through acquisitions and investments, acquiring several subsidiaries. Gilead is a member of the Nasdaq-100 and the S&P 100.
The company has faced criticism over its business practices, including extremely high pricing of drugs such as Sovaldi and Truvada in the United States relative to production cost and cost in the developing world. Wikipedia
Despre Gilead Sciences, Inc
Director executivDaniel O'Day
Angajați17 K
Înființată la22 iun. 1987
SediuFoster City, California, Statele Unite ale Americii
DomeniuHealth Care
Domeniu de activitate-
Sitegilead.com